Esperion Announces Pricing of Public Offering of Common Stock

Core Viewpoint - Esperion Therapeutics, Inc. has announced a public offering of 30 million shares at a price of $2.50 per share, aiming to raise approximately $75 million before expenses [1]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 4.5 million shares [1]. - The offering is expected to close on or about October 9, 2025, pending customary closing conditions [1]. - The shares are being offered under an effective shelf registration statement filed with the SEC on April 18, 2025 [3]. Group 2: Management and Coordination - Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering [2]. - Citizens JMP Securities, LLC, H.C. Wainwright & Co., LLC, and Needham & Company, LLC are co-managers for the offering [2]. Group 3: Company Overview - Esperion is a biopharmaceutical company focused on developing oral, once-daily, non-statin medicines for patients with elevated LDL-C [6]. - The company has FDA-approved medications supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [6]. - Esperion is advancing its pipeline with a focus on developing ATP citrate lyase inhibitors (ACLYi) [6][7].